Literature DB >> 2918052

The natural history of untreated hyperprolactinemia: a prospective analysis.

J Schlechte1, K Dolan, B Sherman, F Chapler, A Luciano.   

Abstract

This report describes the results of a long term prospective study of 30 women with hyperprolactinemia who were not treated and who underwent yearly clinical, hormonal, and radiographic evaluation for an average of 5.2 yr (range 3-7 yr). At entry into the study 18 women had amenorrhea, 8 had oligomenorrhea, and 4 had regular menstrual periods. The initial mean serum PRL levels did not differ in women grouped according to menstrual function. Nine women (35%) had improvement in clinical symptoms. Serum PRL decreased, and menstrual periods normalized more often in those who initially had oligomenorrhea or regular menstrual periods. In most amenorrheic women serum PRL levels did not decline, and menstrual symptoms did not improve. Six of 30 women had an increase in serum PRL, 14 had no change, and 10 had a decrease, in 6 of whom serum PRL was normal at the last observation. Twenty-seven women had serial radiographic studies. Four (15%) of the 13 women with initially abnormal radiographic findings had normal studies later, 2 had tumor progression, and 7 no change. Four of 14 women who had normal radiographic studies initially developed radiographic evidence of a pituitary tumor, although the radiographic changes were minimal, and no patient developed a macroadenoma or pituitary hypofunction. Increases or decreases in serum PRL did not accurately predict changes in tumor size. Prior estrogen use and previous pregnancies did not increase the likelihood of tumor appearance or enhance tumor growth. The clinical presentation of the patient was an important factor in predicting which patients had a decline in serum PRL and resolution of symptoms. We conclude that patients with hyperprolactinemia are unlikely to have progression of their disease and may, in fact, have clinical and radiographic improvement.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2918052     DOI: 10.1210/jcem-68-2-412

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 2.  Medical treatment of prolactinomas.

Authors:  Annamaria Colao; Silvia Savastano
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 3.  Long-term management of prolactinomas--use of long-acting dopamine agonists.

Authors:  David M Cook
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 4.  Prolactinoma through the female life cycle.

Authors:  Deirdre Cocks Eschler; Pedram Javanmard; Katherine Cox; Eliza B Geer
Journal:  Endocrine       Date:  2017-11-24       Impact factor: 3.633

Review 5.  The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons.

Authors:  Alexander T Faje; Anne Klibanski
Journal:  Endocrine       Date:  2014-06-03       Impact factor: 3.633

6.  Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.

Authors:  Fatemeh Mahboobifard; Farahnaz Bidari-Zerehpoosh; Zahra Davoudi; Mahshid Panahi; Leila Dargahi; Mohammad H Pourgholami; Gieve Sharifi; Neda Izadi; Masoumeh Jorjani
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

Review 7.  Diagnosis and management of hyperprolactinemia.

Authors:  Omar Serri; Constance L Chik; Ehud Ur; Shereen Ezzat
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

Review 8.  Managing prolactin-secreting adenomas during pregnancy.

Authors:  Syed Ali Imran; Ehud Ur; David B Clarke
Journal:  Can Fam Physician       Date:  2007-04       Impact factor: 3.275

9.  Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy.

Authors:  M M Garcia; L P Kapcala
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

10.  Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia.

Authors:  P Touraine; C Deneux; G Plu-Bureau; P Mauvais-Jarvis; F Kuttenn
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.